Schizophrenia, Obesity, and Antipsychotic Medications: What Can We Do?

References

• Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999; 282(16): 1523–1529.
   PubMed Web of Science ®Google Scholar
• Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord. 2002; 26(1): 137–141.
   PubMed Web of Science ®Google Scholar
• Goldberg JF, Citrome L. Latest therapies for bipolar disorder. Looking beyond lithium. Postgrad Med. 2005; 117(2): 25–36.
   PubMed Web of Science ®Google Scholar
• Citrome L, Volavka J. The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning. Postgrad Med. 2004; 116(4): 49–63.
   PubMed Web of Science ®Google Scholar
• Citrome L, Volavka J. Atypical antipsychotics: revolutionary or incremental advance? Expert Rev Neurother. 2002; 2(1): 69–88.
   PubMedGoogle Scholar
• Weiden PJ. Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004; 66(1): 51–57.
   PubMed Web of Science ®Google Scholar
• Bray GA. Evaluation of obesity. Who are the obese? Postgrad Med. 2003; 114(6): 19–38.
   PubMed Web of Science ®Google Scholar
• Citrome L. Metabolic syndrome and cardiovascular disease. J Psychopharmacol. 2005; 19(6 supp1): 84–93.
   PubMedGoogle Scholar
• Tan CF., Ma S, Wai D, Chew S K, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care. 2004; 27(5): 1182–1186.
   PubMed Web of Science ®Google Scholar
• Anuurad E, Shiwaku K, Nogi A, et al. The new BMI criteria for asians by the regional office for the western pacific region of WHO are suitable for screening of overweight to prevent metabolic syndrome in elder Japanese workers. J Occup Health. 2003; 45(6): 335–343.
   PubMed Web of Science ®Google Scholar
• James PT, Rigby N, Leach R; International Obesity Task Force. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil. 2004; 11(1): 3–8.
   PubMed Web of Science ®Google Scholar
• Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006; 295(13): 1549–1555.
   PubMed Web of Science ®Google Scholar
• Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999; 60(4): 215–220.
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005; 80(1): 19–32.
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006; 86(1–3): 15–22.
   PubMed Web of Science ®Google Scholar
• Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmä cher T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res. 2003; 37(3): 193–220.
   PubMed Web of Science ®Google Scholar
• Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999; 156(11): 1686–1696.
   PubMed Web of Science ®Google Scholar
• Mclntyre RS, Trakas K, Lin D, et al. Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia. Can J Psychiatry. 2003; 48(10): 689–694.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12): 1209–1223.
   PubMed Web of Science ®Google Scholar
• Citrome L. Stroup TS. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int J Clin Pract. 2006; 60(8): 933–940.
   PubMed Web of Science ®Google Scholar
• Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Stand. 2008; 117(6): 412–419.
   PubMed Web of Science ®Google Scholar
• Citrome L. The effectiveness criterion: balancing efficacy against the risk of weight gain. J Clin Psychiatry. 2007; 68(supp1 12): 12–17.
   PubMedGoogle Scholar
• Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine. risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006; 163(4): 611–622.
   PubMed Web of Science ®Google Scholar
• Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther. 2005; 27(12): 1930–1941.
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003; 23(6): 595–600.
   PubMed Web of Science ®Google Scholar
• Casey DF., Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003; 166(4): 391–399.
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol. 2005; 25(3): 255–258.
   PubMed Web of Science ®Google Scholar
• Lipkovich I, Citrome L, Perlis R, et al. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol. 2006; 26(3): 316–320.
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001; 62(2): 92–100.
   PubMed Web of Science ®Google Scholar
• Brecher M, Leong RW, Stening G, Osterling-Koskinen L, Jones AM. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. J Clin Psychiatry. 2007; 68(4): 597–603.
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Volavka J, Stauffer V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed dose study. J Clin Psychopharmacol. In press.
   Google Scholar
• Lane HY, Chang YC, Cheng YC, et al. Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. J Clin Psychiatry. 2003; 64(3): 316–320.
   PubMed Web of Science ®Google Scholar
• Arvanitis LA, Miller BG. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry. 1997; 42(4): 233–246.
   PubMed Web of Science ®Google Scholar
• Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry. 2000; 61(11): 863–867.
   PubMed Web of Science ®Google Scholar
• Vanina Y, Podolskaya A, Sedky K, et al. Body weight changes associated with psychopharmacology. Psychiatr Serv. 2002; 53(7): 842–847.
   PubMed Web of Science ®Google Scholar
• Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry. 2007; 46(6): 687–700.
   PubMed Web of Science ®Google Scholar
• Strassnig M, Miewald J, Keshavan M, Ganguli R. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res., 2007; 93(1–3): 90–98.
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007; 164(7): 1050–1060.
   PubMed Web of Science ®Google Scholar
• Kahn RS, Fleischhacker WW, Boter H, et al; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008: 371(9618): 1085–1097.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004; 27(2): 596–601.
   PubMed Web of Science ®Google Scholar
• Harmatz MG, Lapuc P. Behavior modification of overeating in a psychiatric population. J Consult Clin Psychol. 1968; 32(5): 583–587.
   PubMedGoogle Scholar
• Wu MK, Wang CK, Bai YM, Huang CY, Lee SD. Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatr Serv. 2007; 58(4): 544–550.
   PubMed Web of Science ®Google Scholar
• Mauri M, Simoncini M, Castrogiovanni S, et al. A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine. Pharmacopsychiatry. 2008; 41(1): 17–23.
   PubMed Web of Science ®Google Scholar
• Alvarez-Jiménez M, Gonzélez-Blanch C, Vézquez-Barquero JL, et al. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial. J Clin Psychiatry. 2006; 67(8): 1253–1260.
   PubMed Web of Science ®Google Scholar
• Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnson CG. The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh. 2003; 35(3): 237–241.
   PubMed Web of Science ®Google Scholar
• Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aust N Z J Psychiatry. 2005; 39(6): 479–86.
   PubMed Web of Science ®Google Scholar
• Vreeland B, Minsky S, Menza M, Rigassio Radier D, Roemheld-Hamm B, Stern R. A program for managing weight gain associated with atypical antipsychotics. Psychiatr Serv. 2003; 54(8): 1155–1157.
   PubMed Web of Science ®Google Scholar
• Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry. 2004; 65(4): 471–477.
   PubMed Web of Science ®Google Scholar
• Ball MP, Coons VB, Buchanan RW. A program for treating olanzapine- related weight gain. Psychiatr Serv. 2001; 52(7): 967–969.
   PubMed Web of Science ®Google Scholar
• Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2005; 66(2): 205–212.
   PubMed Web of Science ®Google Scholar
• K won JS, Choi JS, Bahk WM, et al. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial. J Clin Psychiatry. 2006; 67(4): 547–553.
   PubMed Web of Science ®Google Scholar
• Weber M, Wyne K. A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophr Res. 2006; 83(1): 95–101.
   PubMed Web of Science ®Google Scholar
• Khazaal Y, Fresard E, Rabia S, et al. Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. Schizophr Res. 2007; 91(1–3): 169–177.
   PubMed Web of Science ®Google Scholar
• Brown S, Chan K. A randomized controlled trial of a brief health promotion intervention in a population with serious mental illness. Journal of Mental Health. 2006; 15(5): 543–549.
   Google Scholar
• McKibbin CL, Patterson TL, Norman G, et al. A lifestyle intervention for older schizophrenia patients with diabetes mellitus: a randomized controlled trial. Schizophr Res. 2006; 86(1–3): 36–44.
   PubMed Web of Science ®Google Scholar
• Rotatori AF, Fox R, Wicks A. Weight loss with psychiatric residents in a behavioral self control program. Psychol Rep. 1980; 46(2): 483–186.
   PubMed Web of Science ®Google Scholar
• National Heart Lung and Blood Institute, North American Association for the Study of Obesity. The Practical Guide: Identification. Evaluation. and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Institutes of Health; 2000.
   Google Scholar
• Tsai AG, Wadden TA, Womble LG, Byrne KJ. Commercial and self-help programs for weight control. Psychiatr Clin North Am. 2005; 28(1): 171–192.
   PubMed Web of Science ®Google Scholar
• Dansinger ML, Gleason JA, Griffith, JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA. 2005; 293(1): 43–53.
   PubMed Web of Science ®Google Scholar
• Poole Hoffmann V, Ahl J, Meyers A, et al. Wellness intervention for patients with serious and persistent mental illness. J Clin Psychiatry. 2005; 66(12): 1576–1579.
   PubMed Web of Science ®Google Scholar
• Vreeland B, Toto AM, Sakowitz M. Solutions for Wellness. Ed 3. Indianapolis, IN: Eli Lilly and Co, 2008. In press.
   Google Scholar
• Hill JO, Wyatt HR. Small changes: a big idea for addressing obesity. Obesity Mgmt. 2006; 2(6): 227–231.
   Google Scholar
• Joffe G, Takala P, Tchoukhine E, et al. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008; 69(5): 706–711.
   PubMed Web of Science ®Google Scholar
• Hilger E, Quiner S, Ginzel I, Walter H, Saria L, Barnas C. The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy. J Clin Psychopharmacol. 2002; 22(1): 68–70.
   PubMed Web of Science ®Google Scholar
• Henderson DC, Copeland PM, Daley TB, et al. A double-blind, placebo- controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry. 2005; 162(5): 954–962.
   PubMed Web of Science ®Google Scholar
• Henderson DC, Fan X, Copeland PM, et al. A double-blind, placebo- controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand. 2007; 115(2): 101–105.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Frye MA, Altshuler LL, et al. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. Bipolar Disord. 2007; 9(4): 426–434.
   PubMed Web of Science ®Google Scholar
• Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007; 370(9600): 1706–1713.
   PubMed Web of Science ®Google Scholar
• Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Schizophr Bull. 2007; 33(3): 654–656.
   PubMed Web of Science ®Google Scholar
• Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev. 2007; (1): CD005148.
   Google Scholar
• Baptista T, Uzc´tegui E, Rangel N, et al. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: A 12-week double-blind, placebo-controlled pilot study. Psychiatry Res. 2008; 159(1–2): 250–253.
   PubMed Web of Science ®Google Scholar
• Graham KA, Gu H, Lieberman JA, Harp JB, Perkins DO. Doubleblind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry. 2005; 162(9): 1744–1746.
   PubMed Web of Science ®Google Scholar
• Deberdt W, Winokur A, Cavazzoni PA, et al. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol. 2005; 15(1): 13–21.
   PubMed Web of Science ®Google Scholar
• Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 2003; 13(2): 81–85.
   PubMed Web of Science ®Google Scholar
• Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. Hum Psychopharmacol. 2003; 18(6): 457–461.
   PubMed Web of Science ®Google Scholar
• Atmaca M, Kuloglu M, Tezcan E, Ustundag B, Kilic N. Nizatidine for the treatment of patients with quetiapine-induced weight gain. Hum Psychopharmacol. 2004; 19(1): 37–40.
   PubMed Web of Science ®Google Scholar
• Assunç˜o SS, Ruschel SI, Rosa L de C, et al. Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine. Rev Bras Psiquiatr. 2006; 28(4): 270–276.
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Tal V, Maayan R, Gil-Ad I, Fuchs C, Weizman A. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. Eur Neuropsychopharmacol. 2004; 14(4): 332–336.
   PubMed Web of Science ®Google Scholar
• Wu RR, Zhao JP, Guo XF, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry. 2008; 165(3): 352–358.
   PubMed Web of Science ®Google Scholar
• Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA. 2008; 299(2): 185–193.
   PubMed Web of Science ®Google Scholar
• Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. 2006; 163(12): 2072–2079.
   PubMed Web of Science ®Google Scholar
• Baptista T, Martinez J, Lacruz A, et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry. 2006; 51(3): 192–196.
   PubMed Web of Science ®Google Scholar
• Baptista T, Rangel N, Fernández V, et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res. 2007; 93(1–3): 99–108.
   PubMed Web of Science ®Google Scholar
• Ko YH, Joe SH, Jung IK, Kim SH. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol. 2005; 28(4): 169–175.
   PubMed Web of Science ®Google Scholar
• Kim JH, Yim SJ, Nam JH. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizoph Res. 2006; 82(1): 115–117.
   PubMed Web of Science ®Google Scholar
• Nickel MK, Nickel C, Muehlbacher M, et al. Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo- controlled study. J Clin Psychopharmacol. 2005; 25(3): 211–217.
   PubMed Web of Science ®Google Scholar
• Egger C, Muehlbacher M, Schatz M, Nickel M. Influence of topiramate on olanzapine-related weight gain in women: an 18-month follow-up observation. J Clin Psychopharmacol. 2007; 27(5): 475–478.
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Fuchs C, Pashinian A, et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology (Beri). 2007; 192(3): 441–448.
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Isaacs I. Fuchs C, et al. Attenuation of olanzapine- induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry. 2003; 160(2): 297–302.
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Pashinian A, Gil-Ad I, et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry. 2002; 159(6): 1058–1060.
   PubMed Web of Science ®Google Scholar
• Bustillo JR, Lauriello J, Parker K, et al. Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsy- chopharmacology. 2003; 28(3): 527–529.
   PubMed Web of Science ®Google Scholar
• Lu ML, Lane HY, Lin SK, Chen KP, Chang WH. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry. 2004; 65(6): 766–771.
   PubMed Web of Science ®Google Scholar
• Borovicka MC, Fuller MA, Konicki PE, White JC, Steele VM, Jaskiw GE. Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. J Clin Psychiatry. 2002; 63(4): 345–348.
   PubMed Web of Science ®Google Scholar
• Goodall E, Oxtoby C, Richards R, Watkinson G, Brown D, Silverstone T. A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity. Br J Psychiatry. 1988; 153: 208–213.
   PubMed Web of Science ®Google Scholar
• Modell W, Hussar AE. Failure of dextroamphetamine sulfate to influence eating and sleeping patterns in obese schizophrenic patients: clinical and pharmacological significance. JAMA. 1965; 193: 95–98.
   PubMedGoogle Scholar
• Ding G, Yu G. Zhang J, et al. The therapeutic effects of ling gui zhu gan tang mixture in 50 psychotic patients with obesity induced by the psychoactive drugs. J Tradit Chin Med. 2005; 25(1): 25–28.
   PubMedGoogle Scholar
• Duggal HS. Psychotic symptoms associated with topiramate: cognitive side effects or worsening of psychosis? J Clin Psychiatry. 2004: 65(8): 1145.
   PubMed Web of Science ®Google Scholar
• Hamoui N, Kingsbury S, Anthone GJ, Crookes PF. Surgical treatment of morbid obesity in schizophrenic patients. Obes Surg. 2004; 14(3): 349–352.
   PubMed Web of Science ®Google Scholar
• Sarwer DB, Cohn NI, Gibbons LM, et al. Psychiatric diagnoses and psychiatric treatment among bariatric surgery candidates. Obes Surg. 2004; 14(9): 1148 1156.
   PubMed Web of Science ®Google Scholar
• Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert panel on the identification, evaluation, and treatment of overweight in adults. Am J Clin Nutr. 1998; 68(4): 899–917.
   PubMed Web of Science ®Google Scholar